Core Viewpoint - Royal Philips has announced the acquisition of SpectraWAVE, Inc., which specializes in Enhanced Vascular Imaging (EVI) and AI applications in medical imaging, aimed at improving treatment for coronary artery disease, a condition affecting over 300 million people globally [2][4][6]. Company Overview - Royal Philips is a global leader in health technology, focusing on improving health and well-being through innovation [15][16]. - The company generated sales of EUR 18 billion in 2024 and employs approximately 67,000 people [16]. Acquisition Details - The acquisition of SpectraWAVE will enhance Philips' portfolio in the coronary intervention segment, integrating AI-powered innovations in intravascular imaging and physiological assessment [4][7][9]. - Financial terms of the acquisition have not been disclosed [13]. Technology Integration - SpectraWAVE's HyperVue Imaging System combines DeepOCT and NIRS technologies to provide detailed imaging of coronary arteries during procedures, facilitating rapid setup and automated AI analysis [8][10]. - The X1-FFR technology from SpectraWAVE offers AI-enabled physiological assessments from a single angiogram, enhancing the workflow for percutaneous coronary interventions [11]. Market Impact - The integration of SpectraWAVE's technologies with Philips' Azurion platform is expected to significantly increase the adoption of advanced imaging and physiological assessment in treating coronary artery disease [9][12]. - Philips aims to expand clinician choice and improve patient outcomes through the convergence of intravascular imaging, coronary physiology, and AI [6][7].